Paul Ashton Email and Phone Number
Paul Ashton work email
- Valid
- Valid
- Valid
Paul Ashton personal email
Paul Ashton phone numbers
Seasoned biopharmaceutical CEO with over 15 years of experience, the last 7 as CEO of NASDAQ-listed company. Companies led developed of three of the only four sustained-release products approved by FDA to treat back-of-the-eye diseases; and another product is in Phase III trials. Consummated key collaboration agreements with major pharmaceutical companies. Expert at fund raising and strategic collaborations with over $130M cash received from collaboration and technology evaluation agreements and over $80M from equity offerings. Strong strategic leadership skills, adapting and refocusing strategy as required. Able leader in up and down-side scenarios, leading company through major restructuring to solid financial position. Effective presenter with solid, long-standing Wall Street relationships. Excellent working relationships with FDA. Outstanding team builder with average employee tenure of over 8 years. Management of international operations and shareholder base. Internationally recognized scientist in ophthalmology and drug delivery, frequent presenter at international meetings, author of over 200 peer-reviewed publications and abstracts and holder of over 120 US and international patents.
Psivida Corp.
View- Website:
- eyepointpharma.com
- Employees:
- 213
-
President, Chief Executive Officer And A DirectorPsivida Corp.Watertown, Ma, Us
-
President And CeoInflammasome Therapeutics, Ltd. 2017 - PresentNewly founded company focused on developing new therapies for progressive chronic diseases such as Dry Age-Related Macular Degeneration, Alzheimer’s and type II diabetes.
-
President, Chief Executive Officer And A DirectorPsivida Corp. 2008 - PresentNASDAQ and ASX listed company that is a leader in the development of sustained release drug delivery products to treat eye disease. Led the company’s transition from a technology based Drug Delivery model to a product based Specialty Pharma. model with a rich pipeline of its own products, while simultaneously putting the company on a solid financial footing. Simplified the corporate structure and established solid relationships with Wall Street. Leveraged his excellent relationship with the FDA, gained over 20+ years of direct interaction with the agency, to rapidly advance Medidur™ product into Phase III trials and to guide the approval process of the licensed product ILUVIEN® through the FDA and EU regulatory authorities a successful conclusion. Key Accomplishments: • Reincorporated pSivida Limited from an Australian to a US corporation• Consummated $45M in public offerings and private placements• Renegotiated Alimera collaboration agreement for consideration of $78M plus 20% profit split ($55M in cash received and elimination of financial responsibility for development) • Renegotiated Pfizer agreement to return intellectual property to pSivida and focus solely on bioerodible implant for glaucoma with $12M up-front payments $20M option exercise fee and potential milestone payments of up to $146.5M plus double digit royalties• Initiated Phase III clinical trials for Medidur™, an injectable sustained release micro-insert for posterior uveitis; NDA planned in 2017
-
Managing Director (Ceo) 2008, Director Of Strategy 2006-2007, DirectorPsivida Corp. 2006 - 2008ASX and NASDAQ listed global bio-nanotech companyCompleted a corporate turn-around and saved the company from bankruptcy. This was achieved by refocusing the company’s strategic goals, consolidating operations, realigning investor relations and corporate communications and leverage excellent reputation in Ophthalmology into a key licensing agreement with Pfizer. Key Accomplishments: • Negotiated collaborative research and licensing agreement with Pfizer for pSivida’s drug delivery technology in ophthalmic applications in return for up to $155M in milestones, single digit royalties and $11M equity investment• Rationalized company research program to focus on core Durasert™ and BioSilicon™ technologies, out-licensed or sold non-core products and technologies and narrowed geographic scope of company closing subsidiaries in Singapore and Australia • Refinanced company’s capital structure to eliminate death-spiral debt
-
Company Founder, President And Ceo 1996-2005; Vice President, Head Of R&D 1992-1995Control Delivery Systems 1992 - 2005Co-founder of this start-up company (CDS) focused on developing sustained release drug delivery products. Created the technology platform on which the company was based. Built out the infrastructure of the company and established corporate credibility with collaborations with key partners (Chiron and Bausch and Lomb) resulting in two product approvals. He also worked to established relationships with analysts and banks culminating in at $34M Series A financing with Deutche Bank.and a subsequent exit via a$104M acquisition. Key Accomplishments:• Developed patented 1st generation Durasert technology for Vitrasert®, a surgical implant providing sustained delivery of CMV retinitis for 6-8 months • Consummated collaboration and license agreement with Chiron Corporation valued at $8M for the joint development and marketing of Vitrasert• Vitrasert approval in the US and EU• Developed patented 2nd generation Durasert technology for Retisert®, a surgical implant providing sustained treatment of uveitis for 36 months • Consummated collaboration agreement with Bausch & Lomb providing for the joint development and marketing of Vitrasert, Retisert and 2 development products valued at $206M plus royalties• Consummated advance royalty funding• Completed $34M Series A financing with leading venture capital firms mutual funds• Developed patented 3d generation Durasert technology for ILUVIEN, an injectable micro-insert providing 36 months of sustained delivery to treat diabetic macular edema• Consummated collaboration and license agreement with Alimera Sciences for the joint development and marketing of ILUVIEN• Consummated $104M acquisition of CDS -
Assistant Professor OphthalmologyNew England Eye Center 1995 - 2000Boston, Ma, Us -
Assistant Professor, Joint Appointments In Ophthalmology, Neurosurgery And PharmacologyUniversity Of Kentucky 1988 - 1994Lexington, Ky, Us -
Research Scientist (Pre-Ph.D)Roche 1983 - 1984Switzerland 🇨🇭 , Ch
Paul Ashton Skills
Paul Ashton Education Details
-
University Of Wales, CardiffPharmaceutical Sciences -
University Of Southern CaliforniaPost Doctoral Fellowship
-
Durham UniversityHonors
Frequently Asked Questions about Paul Ashton
What company does Paul Ashton work for?
Paul Ashton works for Psivida Corp.
What is Paul Ashton's role at the current company?
Paul Ashton's current role is President, Chief Executive Officer and a Director.
What is Paul Ashton's email address?
Paul Ashton's email address is pa****@****ida.com
What is Paul Ashton's direct phone number?
Paul Ashton's direct phone number is +161792*****
What schools did Paul Ashton attend?
Paul Ashton attended University Of Wales, Cardiff, University Of Southern California, Durham University.
What skills is Paul Ashton known for?
Paul Ashton has skills like Biotechnology, Pharmacology, Clinical Trials, Venture Capital, Ophthalmology, Pharmaceutics, Drug Delivery, Life Sciences, Start Ups, Fda, Strategy, R&d.
Who are Paul Ashton's colleagues?
Paul Ashton's colleagues are Brandon Heng, Annette Leblanc, Sambath Ok, Ahalya Viswanathan Phd, Pmp, Daniel Bento, Joie Tsang, Ana Peralta.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial